Aroa Biosurgery’s Symphony Trial Completion: What Diabetic Ulcer Data Could Mean for AU:ARX

Aroa Biosurgery Ltd (AU:ARX) announced an update on their ongoing clinical study.

Study Overview: This completed clinical study, titled “A Multi-Center, Randomized Controlled Clinical Investigation Evaluating Wound Closure With Symphony™ Versus Standard of Care in the Treatment of Non-Healing Diabetic Foot Ulcers,” tested whether Aroa Biosurgery’s Symphony™ device could improve healing of stubborn diabetic foot ulcers versus current standard dressings. The goal was to measure safety and how many ulcers closed after 12 weeks, an important outcome for reducing infection, amputation risk, and overall treatment cost in a growing diabetes market.

Intervention/Treatment: The trial compared two wound care approaches. The test group received Symphony™ plus off-loading, a device-based treatment designed to support wound closure and tissue repair. The control group received standard care, using a calcium alginate Fibracol dressing plus off-loading. Both are devices placed directly on the wound, but Symphony™ aims to offer better, faster healing.

Study Design: This was an interventional, randomized study where patients were randomly assigned to either Symphony™ or standard care. The design used two parallel groups that were treated and followed at the same time. It was open label, meaning doctors and patients knew which treatment they were getting. The main purpose was treatment: to see which option led to better wound closure and safety in routine practice.

Study Timeline: The study was first submitted to the registry on 23 August 2023, marking the start of public tracking and signaling early development progress to investors. The trial is now listed as completed, indicating all patient treatment and key follow-up are done, and data analysis can move forward. While results have not yet been posted, the listing was last updated on 26 January 2026, confirming that the record is current and the sponsor is actively managing the study data.

Market Implications: For Aroa Biosurgery, a positive outcome from this study could strengthen the commercial case for Symphony™ in diabetic foot care, a segment with high costs and strong demand for better healing solutions. Evidence that Symphony™ outperforms standard dressings could support higher pricing, wider reimbursement, and faster adoption in wound care centers, improving revenue visibility and sentiment toward AU:ARX. Until full results are disclosed, investors may treat the update as a sign of execution progress but remain cautious. Competitors in advanced wound care, including large diversified medtechs and specialized wound companies, are also targeting diabetic ulcers, so clear clinical advantages and cost-effectiveness will be key to Aroa’s ability to gain share. The study is now completed and recently updated, with further details available on the ClinicalTrials portal.